Top Value Stocks For 2019: October 2014

Friday, October 31, 2014

Hot Blue Chip Stocks To Own Right Now

Hot Blue Chip Stocks To Own Right Now: McDonald's Corporation(MCD)

McDonald?s Corporation, together with its subsidiaries, operates as a worldwide foodservice retailer. It franchises and operates McDonald?s restaurants that offer various food items, soft drinks, coffee, and other beverages. As of December 31, 2009, the company operated 32,478 restaurants in 117 countries, of which 26,216 were operated by franchisees; and 6,262 were operated by the company. McDonald?s Corporation was founded in 1948 and is based in Oak Brook, Illinois.

Advisors' Opinion:

[By Ben Levisohn]
McDonald’s (MCD) is a disappointment. Its most recent earnings and revenue numbers were below the Street consensus. Its same-store sales are sliding. And its shares have dropped 4.8% so far this year, underperforming the S&P 500 by nearly 12 points. In fact, all that investors have at this point is a pledge for change, and that’s likely to disappoint too.
Getty Images
Unless it doesn’t. That plus the fast-food giant’s heft dividend are enough justification to buy McDonald’s, says UBS analyst Keith Siegner and team. He explains:

This has been a frustrating year and could remain so as competition cont. to effectively execute and innovate against what appears not enough from MCD in months ahead. We are becoming increasingly discouraged that the current plan will be sufficient to close the comp gap to sandwich/burger peers (widened to -630 bps in Sept), let alone NT. It’s also unclear whether McDonald’s will truly address ownership, capital and cost structure opportunities. However, we still see significant potential to unlock value through multiple avenues, both operational and strategic corporate actions. Further, we are encouraged that despite results which were even more disappointing than prior quarters, shares were only down slightly, highl! ighting the support from low expectations and valuation and w/ a ~3.7% div. yield. Combined, we view the risk/reward as favorable and remain Buy.

Shares of McDonald’s have gained 0.4% to $92.36 at 2:43 p.m. today, while Wendy’s (WEN) has risen 0.6% to $8.06 and Burger King (BKW) has dropped 1.2% to $31.72.
[By Jesse Solomon]
The impressive results are instructive at a time when other restaurant chains, including McDonalds (MCD) and rival Pizza Hut owner Yum! Brands (YUM), can't get their act together.
[By Anders Bylund]
Let's take a look at three classic dividend growers: Procter & Gamble (NYSE: PG ) , Altria Group (NYSE: MO ) , and McDonald's (NYSE: MCD ) . These classic cash machines have increased their payouts without fail for at least 37 consecutive years, creating heaps of investor wealth in the process.
[By Ben Levisohn]
McDonald’s (MCD) has a problem. Investors have known this for a while, and now it seems McDonald’s management does too.
Associated Press
McDonald’s reported a profit of $1.35 a share not including charges, missing forecasts for $1.37. Even worse–same-store sales in the U.S. and Europe slumped the most since 2003. Janney’s Mark Kalinowski and Ryan Kidd explain:

September same-store sales in the U.S. fell by -4.1%, which was even worse than our sell-side low projection of -3.6% (and also below the Consensus Metrix figure of -2.8%).

The -4.1% number was also the worst monthly McDonald's U.S. same-store sales performance since February 2003's -4.4%. Perhaps an even greater surprise was Europe's September same-store sales decline of -4.2%, which was worse than our -1.0% projection, and below the Consensus Metrix number of -0.9%. The poor European showing was the worst month for McDonald's same-store sales in that key region since March 2003's -5.4% decline. Although APMEA (Asia/Pacific! , Middle ! East, & Africa) September same-store sales of -7.5% were better than our -11.0% estimate and Consensus Metrix of -11.0%, it's obviously not a performance to crow about, either.

The good news is that McDonald’s finally acknowledged that it has a problem. It plans to simplify its menu, among other steps. It might take bigger steps, however, before investors can start believing in McDonald’s again.

Shares of McDonald’s have dipped 0.3% to $91.35 at 12:28 p.m.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-blue-chip-stocks-to-own-right-now-2.html

Top 5 Medical Stocks To Own For 2014

Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:

AVEO Pharmaceuticals. Founded on a unique drug discovery and development approach called the Human Response Platform, AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies. Back in June, AVEO Pharmaceuticals announced that it had received a Complete Response letter from the FDA denying approval in its present form the New Drug Application (NDA) for AVEO�� investigational agent tivozanib for the treatment of patients with advanced metastatic renal cell carcinoma as they want an additional clinical study. AVEO Pharmaceuticals then announced a major strategic restructuring�to refocus efforts on the on-going clinical development of tivozanib in colorectal and breast cancer and on the advancement of other key pipeline and preclinical assets.

5 Best Promising Stocks To Buy For 2015: Medifocus Inc (MDFZF)

Medifocus Inc.(Medifocus) is a Canada-based company. The Company is engaged in the business of development and commercialization of minimally invasive, focused-heat tumor targeted cancer treatment devices and systems. Medifocus operates through its wholly owned subsidiary, Celsion (Canada) Limited (Celsion). Celsion had purchased from Celsion Corporation (United States), all of the assets relating to breast cancer Microfocus APA 1000 System (System), consisting of the microwave machine, the adaptive phased array (APA) technology licensed from Massachusetts Institute of Technology (MIT). The Company focuses on breast cancer treatment by using microwave heating to enhance neoadjuvant chemotherapy to provide tumor shrinkage and control. Advisors' Opinion:

[By Peter Graham]
Small cap stocks KBridge Energy Corp (OTCMKTS: BMMCF), Medifocus Inc (OTCMKTS: MDFZF) and Inscor Inc (OTCMKTS: IOGA) have been getting some attention lately in various investment newsletters and some of it is deserved as the first stock sank 35% on Friday, the second one recently released its financials (which did show a big improvement, but there is also a big catch for investors) and the third one has been the subject of a very aggressive promotional campaign. But are any of these three small caps really all that hot for investors? Here is a quick reality check:
[By EquityOptionsGuru]
Over the past few years, and especially months, biotechnology stocks have been soaring on heightened investor expectations. Investors looking for a unique opportunity to participate in a massive bull rally over the next few years might want to pay special attention to one small but growing company called Medifocus (OTCMKTS:MDFZF).

Top 5 Medical Stocks To Own For 2014: Cambridge Heart Inc (CAMH)

Cambridge Heart, Inc., incorporated on January 16, 1990, is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company's products incorporate its technology for the measurement of Microvolt T-Wave Alternans (MTWA). The MTWA Test is conducted by elevating the patient's heart rate through exercise as performed on a treadmill similar to a stress test, pharmacologic agents, or pacing with electrical pulses.

The Company's products, including its first generation HearTwave System and second generation HearTwave II System, CH 2000 Cardiac Stress Test System, MTWA original equipment manufacturer (OEM) Module (MTWA Module) and Micro-V Alternans Sensors have received 510(k) clearance from the United States Food and Drug Administration (FDA) for sale in the United States. The Company's products have also received the Conformite Europeenne (CE) mark for sale in Europe. The Company's first generation HearTwave System, CH 2000 Cardiac Stress Test System and the HearTwave II System have been approved for sale by the Japanese Ministry of Health Labor and Welfare.

The Company's 510(k) clearance allows the Company's MTWA Test to be used to test patients with known, suspected, or at risk of ventricular tachyarrhythmia and/or sudden cardiac arrest, and allows the claim that its MTWA Test is predictive of those events. The MTWA Module is designed to work with existing cardiac stress test platforms distributed by other manufacturers as an add-on module to enable MTWA testing to be performed using the Company's Micro-V Alternans Sensors.

The Company's HearTwave II System, which has replaced the Company's original HearTwave System, is used to perform both MTWA testing and standard cardiac stress testing. In addition to MTWA measurement, the Company's HearTwave II System is a cardiac diagnostic system designed to support a range of customized protocols for the conduct of cardiac exercise stress testing. The Comp! any's Micro-V Alternans Sensors are single patient use, multi-segment electrodes. The Company's CH2000 is a cardiac diagnostic system designed to support a range of customized protocols for the conduct and measurement of cardiac exercise stress testing.

The Company competes with GE Medical Systems.

Advisors' Opinion:

[By Peter Graham]
Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:
Cambridge Heart, Inc (OTCMKTS: CAMH) Recently Changed Its Board
Small cap Cambridge Heart, Inc is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. On Friday, Cambridge Heart, Inc surged 176.92% to $0.018 for a market cap of $1.80 million plus CAMH is up 20% since the start of the year and down 86.1% over the past five years according to Google Finance.

Top 5 Medical Stocks To Own For 2014: Antares Pharma Inc (ATRS)

Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�� subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.

In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.

Pressure Assisted Injection Devices

The Company�� Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.

Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.

The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and disposable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.

Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company�� multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.

Transdermal Products

The Company�� ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.

The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.

Advisors' Opinion:

[By Keith Speights]
Antares Pharma (NASDAQ: ATRS ) announced its first-quarter results �Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.
[By Monica Gerson]
Antares Pharma (NASDAQ: ATRS) shares tumbled 3.09% to touch a new 52-week low of $3.14. Antares Pharma's PEG ratio is -0.29.

eGain (NASDAQ: EGAN) shares fell 3.76% to reach a new 52-week low of $6.40. eGain's trailing-twelve-month ROE is -8.92%
[By Keith Speights]
1. Antares Pharma (NASDAQ: ATRS )
Antares has experienced a roller-coaster ride so far this year. The stock was up more than 10% early in January, then proceeded to fall by more than 20% by late February. Since then, Antares has clawed its way back and now stands up a little over 10% for the year.�

Top 5 Medical Stocks To Own For 2014: Agios Pharmaceuticals Inc (AGIO)

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company�� ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (IEMs) are treated. The Company has identified and validated novel and druggable targets in both cancer and IEMs. The Company�� two advanced cancer programs are targeting mutations in the enzymes isocitrate dehydrogenase 1 and 2, referred to as IDH1 and IDH2. The Company�� drug candidates are selective for the mutated forms of IDH1 and IDH2 found in cancer cells versus the normal forms of IDH1 and IDH2 found in all other cells.

The Company focused on developing medicines to address IEMs, with a novel approach to these orphan diseases for which no effective or disease-modifying therapy is available. The Company has also de-validated and terminated numerous programs, including many that have been reported in scientific journals. In the Company�� IEM portfolio, it uses an equally rigorous set of validation techniques.

Advisors' Opinion:

[By Jake L'Ecuyer]
Shares of Agios Pharmaceuticals (NASDAQ: AGIO) got a boost, shooting up 29.08 percent to $40.84 after the company reported quarterly results.

Stage Stores (NYSE: SSI) was also up, gaining 13.47 percent to $22.41 after the company reported Q4 results and announced the sale of its Steele's off-price division to a new retail unit of Hilco Global.
[By Jake L'Ecuyer]
Equities Trading UP
Sangamo Biosciences (NASDAQ: SGMO) shot up 16.32 percent to $22.81 announced the publication in the NEJM of the first-in-man study of genome editing using its ZFN technology. Shares of Agios Pharmaceuticals (NASDAQ: AGIO) got a boost, shooting up 27.72 percent to $40.41 after the company reported quarterly results. BJ's (NASDAQ: BJRI) was also up, gaining 21.04 percent to $33.48 after the company was upgraded toa Buy rating at Buckingham research.
[By Lisa Levin]
Agios Pharmaceuticals (NASDAQ: AGIO) shares touched a new 52-week low of $18.83. Agios Pharmaceuticals' trailing-twelve-month profit margin is -102.87%.

Wednesday, October 29, 2014

Top 5 Semiconductor Stocks To Watch For 2015

Top 5 Semiconductor Stocks To Watch For 2015: Fairchild Semiconductor International Inc (FCS)

Fairchild Semiconductor International, Inc. (Fairchild) focuses on developing, manufacturing and selling power analog, power discrete and certain non-power semiconductor solutions to a range of end market customers. The Company is a supplier of power analog products, power discrete products and energy-efficient solutions, according to iSuppli. Its products are used in a range of electronic applications, including sophisticated computers and Internet hardware; communications, including wireless phones; networking and storage equipment; industrial power supply and instrumentation equipment; consumer electronics, such as digital cameras, displays, audio/video devices and household appliances, and automotive applications.

The Companys product groups are organized by the end markets, which include Mobile, Computing, Consumer and Communication (MCCC), Power Conversion, Industrial and Automotive (PCIA) and Standard Discrete and Standard Linear (SDT). It invested in the wafer fabrication power semiconductor technology, including low and mid voltage PowerTrench, advanced insulated gate bipolar transistor (IGBT), as well as advanced high power metal oxide semiconductor field effect transistors (MOSFET) fabrication technologies.

Mobile, Computing, Consumer and Communication (MCCC)

The Company designs, manufactures and markets high-performance analog and mixed signal integrated circuits, low voltage power MOSFETs for mobile, consumer, computing, and communication applications. It has a portfolio of PowerTrench technology products. Its analog and mixed signal products are focused on the mobile end- markets.

Analog products monitor, interpret, and control continuously variable functions, such as light, color, sound, and energy. It forms the interface with the digital world. It provides a range of analog products that perform such tasks as voltage regulation! , audio amplification, power and signal swi tching and system management. Analog voltage regulation circ! uits are used to provide constant voltages, as well as step up or step down voltage levels on a circuit board. These products enable improvements in power efficiency, lighting management, and improve charge times in ultraportable products. These products are used in a variety of mobile, computing, communications and consumer applications.

In addition to the power analog and interface products, it also offers signal path products. These include analog and digital switches, universal serial bus (USB) switches, video filters and high performance audio amplifiers. The analog switch functions are typically found in cellular handsets and other ultra portable applications. The video products provide a single chip solution to video filtering and amplification. Video filtering applications include set top boxes and digital television. Its solutions include surface mount devices, tiny packages, chip scale packages, and leadless carriers.

The Company also de sign, manufacture and market power semiconductor solutions for computing, communications, mobile, consumer and industrial applications. Power semiconductor solutions include, power discrete MOSFETs, analog integrated circuits, and fully integrated multi-chip and monolithic power solutions. Its power MOSFETs are primarily used in power delivery and power control applications. Power delivery and control applications are ubiquitous across data consumption, processing and communication applications. It produces advanced low power MOSFETs under its PowerTrench brands. The advanced power MOSFETs applications are used in smartphones, tablets, notebook personal computer, high performance gaming, home entertainment systems, servers, data communication, and routers.

The Company competes with Analog Devices, Inc., Linear Technology Corporation, Maxim Integrated Product, Inc., Micrel Inc, ON Semiconductor Corporation, ST Mi! croelectr! onics N.V., Intersil Corporation, Interna tional Rectifier Corporation, Infineon Technologies AG and T! exas Inst! ruments Incorporated.

Power Conversion, Industrial and Automotive (PCIA)

Fairchild design, manufacture and market power discrete semiconductors, analog and mixed signal integrated circuits (ICs) for broad power conversion/power management, industrial, and automotive applications. Its products are building blocks that help convert a semi-regulated energy source (alternating current (AC)or direct current (DC)) to a regulated output for electronic systems (AC-DC, DC-AC, and DC-DC conversion). Its discrete devices are individual diodes or transistors that perform power switching, power conditioning and signal amplification functions in electronic circuits. The Companys analog and mixed signal integrated circuits (IC) are used to control discrete semiconductors in applications, such as power switching, conditioning, signal amplification, power distribution and power consumption. It manufacture discrete products using vertical DMOS MOSFETs, Insulated Gate Bipolar Transistors (IGBT), Bipolar, and ultrafast rectifier technologies. It manufacture analog and mixed signal ICs using a range of bipolar (Bi), complementary metal oxide (CMOS), BiCMOS, and bipolar/CMOS/DMOS (BCDMOS) processes up to 1,200 volts and down to 0.35um (microns) minimum geometry.

Power MOSFETs are used in applications to switch, shape or transfer energy. These products are used in a range of high-growth applications, including solar inverters, uninterruptible power supplies (UPS), data centers and communications, motors, lighting, automotive, computing, displays and industrial supplies. It produce advanced power MOSFETs under its SupreMOS, SuperFET, PowerTrench, UniFET and QFET brands. IGBTs are high-voltage power discrete devices. They are used in switching applications for solar inverters, uninterruped power supply, data centers and communications, motors, industrial, power supplies! , display! s, television and automotive ignition systems. T hese applications require lower switching frequencies, highe! r power, ! and/or higher voltages than a power MOSFET can provide. It is a supplier of IGBTs. Rectifier products work with IGBTs and MOSFETs in many applications to provide power conversion and conditioning. Its product is the STEALTH rectifier, providing industry performance and efficiencies in data communications, industrial power supply, displays, television, and motor applications.

Leveraging its power MOSFET and IGBT technologies, it also design and manufacture modules for the industrial, automotive, and home appliance end markets. It design and develop a line of smart power modules (SPM) products targeted to various end applications in consumer white goods and industrial applications, which include room air conditioners, industrial power supplies, solar inverters, pumps, and industrial motors. These are multi-chip modules containing up to 28 components in a single package that includes diodes, power discrete IGBTs or MOSFETs, high voltage power management driver ICs and current and temperature sensors. Similar modules, called APM, are used in automotive applications.

The Company design and manufacture power management semiconductors for line-powered and off-line powered systems that integrate its Power MOSFETs. It sell and market off-line and isolated DC-DC ICs, MOSFET and IGBT gate driver ICs, and power factor correction ICs to the consumer, computing, display, television, lighting and industrial segments.

The Company competes with Infineon Technologies AG, ST MicroelectronicsN.V., International Rectifier Corporation, Toshiba Corporation, Mitsubishi Corporation, Texas Instruments Incorporated, Power Integrations, Inc., ON Semiconductor Corporation, NXP Semiconductors N.V. and Vishay Intertechnology, Inc.

Standard Linear and Standard Discrete (SDT)

Standard Diodes and Transistors products cover a range of semiconductor pro! ducts, in! cluding MOSFET, junction field effect transistors (JFETs), high power bipolar, discrete small signal transistors, TVS,! Zeners, ! rectifiers, bridge rectifiers, Schottky devices and diodes. The Company design, manufacture and market analog integrated circuits for computing, consumer, communications, ultra-portable and industrial applications. These products are manufactured using bipolar, CMOS and BiCMOS technologies. Standard Linear solutions range from bipolar regulators, shunt regulators, low drop out regulators, standard op-amp/comparators, low voltage op-amps, and others. Analog voltage regulator circuits are used to provide constant voltages, as well as to step up or step down voltage levels on a circuit board. Op-amps/comparators are designed specifically to operate from a single power supply over a range of voltages. It also offer low-voltage op-amps that provide a combination of low power, rail-to-rail performance, low voltage operation, and tiny package options which are well suited for use in personal electronics equipment. Its solutions include surface mount devices, tiny packages and leadl ess carriers.

The Company competes with International Rectifier Corporation, Diodes Incorporated, NXP Semiconductors N.V., ST Microelectronics N.V., ON Semiconductor Corporation, Texas Instruments Incorporated, Vishay Intertechnology, Inc., Vishay Intertechnology, Inc, Osram Opto Semiconductors, OPTEK Technology, OMRON Corporation, Avago Technologies Ltd. and Kodenshi Corp.

Advisors' Opinion:

[By Alex Planes]
In an epochal paper published in Electronics magazine on April 19, 1965 and simply titled "Cramming more components onto integrated circuits," Fairchild Semiconductor (NYSE: FCS ) director of research Gordon E. Moore wrote (emphasis mine):
[By rsconsultant]
Fairchild Semiconductor (FCS) wasn't fit as a fiddle at the close of 2013. Feeble orders from Samsung (SSNLF), one of its biggest customers, kept Fairchild dow! n, and it! was not able to take advantage of its supplier relationship with Apple (AAPL).
[By Seth Jayson]
Fairchild Semiconductor International (NYSE: FCS ) reported earnings on April 18. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Fairchild Semiconductor International met expectations on revenues and missed expectations on earnings per share.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-5-semiconductor-stocks-to-watch-for-2015.html

Tuesday, October 28, 2014

5 Best Gas Utility Stocks To Buy Right Now

5 Best Gas Utility Stocks To Buy Right Now: Sienna Resources Inc (SIE)

Sienna Resources Inc, formerly Habanero Resources Inc. is engaged in the identification, acquisition, exploration of mineral properties. These properties include gold, silver, and aluminous clay properties. The Companys mineral property interests were located in Canada. Its mineral properties include White Gold Claims, Grande-Vallee North aluminous clay prospect, Haldane Silver Prospect and Lezai Prospect. The Ross Silver Property consists of approximately 44 contiguous mineral claims, adjoining the existing Haldane Silver Property. In May 2013, the Company acquired an additional 32 claims totaling 1,805 hectares in the Gaspe Bay region of Quebec. Advisors' Opinion:

[By Alexis Xydias]
Loans of shares on Paris-based Renault, Frances second-largest carmaker, account for 0.92 percent, down from 2.25 percent in 2011 as the shares more than doubled, the data show. Stock on loan in Siemens AG (SIE), Europes largest engineering company, has declined to 0.78 percent of shares outstanding from 3.2 percent two years ago, Markit data show. Shares of Munich-based Siemens climbed 33 percent in that time.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-gas-utility-stocks-to-buy-right-now-2.html

5 Best Blue Chip Stocks To Invest In Right Now

With investors cashing in their gains heading into the end of the year, blue chip stocks suffered their worse one-day drop in a month

The Dow Jones Industrial Average at one point fell as much as 134 points, before paring losses. But it still closed below 16,000, falling 94.1 points, or 0.6% to end at 15,914.6.

The Walt Disney Company (DIS) weighed on the index after B. Riley cut its rating on the company, calling it ��airly expensive.��The shares fell 1.4% to close at $69.60

The S&P 500 index dropped 5.7 points, or 0.3%, to 1,795.15. The Nasdaq Composite slipped eight points, or 0.2%, to 4,037.2.

Last week ended with the S&P 500 posting its longest string of weekly advances in almost a decade. As a result, investors are worried the market has become overbought.

Meanwhile, taper talk continues to weigh on investor sentiment, fueling the third straight session of losses for U.S. stocks. On Monday, stronger-than-expected data on manufacturing and construction spending on underscored views the Federal Reserve may soon begin scaling the $85 billion-a-month bond-buying program credited by may for fueling the 2013 stock market rally.

Best Growth Companies For 2015: Apple Inc.(AAPL)

Apple Inc., together with subsidiaries, designs, manufactures, and markets personal computers, mobile communication and media devices, and portable digital music players, as well as sells related software, services, peripherals, networking solutions, and third-party digital content and applications worldwide. The company sells its products worldwide through its online stores, retail stores, direct sales force, third-party wholesalers, resellers, and value-added resellers. In addition, it sells third-party Mac, iPhone, iPad, and iPod compatible products, including application software, printers, storage devices, speakers, headphones, and other accessories and peripherals through its online and retail stores; and digital content and applications through the iTunes Store. The company sells its products to consumer, small and mid-sized business, education, enterprise, government, and creative markets. As of September 25, 2010, it had 317 retail stores, including 233 stores in the United States and 84 stores internationally. The company, formerly known as Apple Computer, Inc., was founded in 1976 and is headquartered in Cupertino, California.

Advisors' Opinion:

[By Jonathan Berr]
Sure, Amazon stock analysts think AMZN is a buy. But I simply can’t wrap my head around the fact that Amazon stock trades at disgusting 140 times expected 2014 earnings. That’s a huge premium to Google�(GOOG) stock, which has also been going strong, yet sports a multiple of just 20. And Apple�(AAPL) stock goes for just 11 times forward earnings.
[By Travis Hoium]
Speaking of wearable products, Apple (NASDAQ: AAPL ) jumped 3.8% today on word that the company has filed for an "iWatch" trademark in Japan. The company also got an upgrade from Raymond James analyst Travis McCourt, who predicts a new product cycle in the second half of the year that will include more mobile products. I, for one, think shares of Apple are cheap whether or not there's an iWatch coming, but the stock won't likely get a major boost until some product is released that will provide a catalyst. At the very least, millions of investors will be awaiting whatever Apple has up its sleeve next. �
[By Victor Reklaitis]
The Nasdaq Composite (COMP) �tacked on 2.34 points, or less than 0.1%, to 3,922.04. The tech-heavy index was hurt by a 0.5% drop for Apple Inc. (AAPL) , which began selling its new iPad Air in its retail stores on Friday.
[By Ben Levisohn]
Tesla, however, was already under pressure this morning, even before Yellen started talking. Some of that might be attributed to the news that BMW had struck a deal with Samsung SDI, who makes batteries for Apple (AAPL) and has recently expanded into the auto business, to spend billions of dollars on batteries for its cars. Competition here we come.

5 Best Blue Chip Stocks To Invest In Right Now: Philip Morris International Inc(PM)

Philip Morris International Inc., through its subsidiaries, engages in the manufacture and sale of cigarettes and other tobacco products in markets outside of the United States. Its international product brand line comprises Marlboro, Merit, Parliament, Virginia Slims, L&M, Chesterfield, Bond Street, Lark, Muratti, Next, Philip Morris, and Red & White. The company also offers its products under the A Mild, Dji Sam Soe, and A Hijau in Indonesia; Diana in Italy; Optima and Apollo-Soyuz in the Russian Federation; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics, and Number 7 in Canada; Best and Classic in Serbia; f6 in Germany; Delicados in Mexico; Assos in Greece; and Petra in the Czech Republic and Slovakia. It operates primarily in the European Union, Eastern Europe, the Middle East, Africa, Asia, Canada, and Latin America. The company is based in New York, New York.

Advisors' Opinion:

[By Matthew Coffina]
Philip Morris International (PM)

Among our holdings, Philip Morris is arguably the most exposed to depreciating emerging market currencies, since it doesn�� have any US sales. Unfortunately, currency fluctuations are an unavoidable tradeoff for emerging markets��relatively stable cigarette volumes.
[By Patricio Kehoe]
Phillip Morris International Inc. (PM) is the world�� largest tobacco manufacturer in the world, after China National Tobacco, and holds 29% of the entire industry�� market, outside the U.S and China. Most commonly known for its flagship brand, Marlboro (accounts for one-third of total volume), this firm also owns seven of the 15 international leading cigarette brands. Its supporting brands ��&M, Phillip Morris, Bond Street, Parliament, Chesterfield and Lark ��ave allowed the company to attain consistent growth margins over the past decade. Given its addictive product and global manufacturing and distribution system, this comes as little surprise.
[By Efficient Alpha]
Philip Morris International (PM) is a favorite of mine, not only for its 4% dividend but also for its protection against global inflationary pressures. The company can pass through higher commodity prices and smokers will keep coming back for more. The company has 16% of the international market and is making strong progress in China. Asia accounts for 36% of sales, followed by the EMEA region (27%), the EU (26%) and Latin America/Canada (11%). Shares have posted an annual return of 15% since its spinoff in 2008.
[By Bill Maurer]
Philip Morris (PM):
Philip Morris saw a surprise short interest drop of more than 20% during the final two weeks of March. More than 2.5 million of the roughly 12.2 million shares short were covered, stopping the recent rise in short interest that you can see in the chart below.

5 Best Blue Chip Stocks To Invest In Right Now: Chevron Corporation(CVX)

Chevron Corporation, through its subsidiaries, engages in petroleum, chemicals, mining, power generation, and energy operations worldwide. It operates in two segments, Upstream and Downstream. The Upstream segment involves in the exploration, development, and production of crude oil and natural gas; processing, liquefaction, transportation, and regasification associated with liquefied natural gas; transportation of crude oil through pipelines; and transportation, storage, and marketing of natural gas, as well as holds interest in a gas-to-liquids project. The Downstream segment engages in the refining of crude oil into petroleum products; marketing of crude oil and refined products primarily under the Chevron, Texaco, and Caltex brand names; transportation of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car; and manufacture and marketing of commodity petrochemicals, plastics for industrial uses, and fuel and lubricant additives. It a lso produces and markets coal and molybdenum; and holds interests in 13 power assets with a total operating capacity of approximately 3,100 megawatts, as well as involves in cash management and debt financing activities, insurance operations, real estate activities, energy services, and alternative fuels and technology business. Chevron Corporation has a joint venture agreement with China National Petroleum Corporation. The company was formerly known as ChevronTexaco Corp. and changed its name to Chevron Corporation in May 2005. Chevron Corporation was founded in 1879 and is based in San Ramon, California.

Advisors' Opinion:

[By Travis Hoium]
Chevron (NYSE: CVX ) is down the most on the Dow today, falling 1.3%. Oil is actually up 1.1% today,�but the real challenge for big oil is the rising cost of oil extraction and falling demand in developed markets. In the U.S., daily oil demand is down 10.2% since 2007, and that's a concerning development for energy investors. Explorers are also looking for oil in difficult drilling locations like ultra-deep water and shale here in the U.S. These two issues will be important for current and prospective energy-sector investors to follow. �
[By Jim Jubak]
First, the cancellation of Shell's project emphasizes the huge first-mover advantage that Cheniere has. Future plants to be built by competitors will face much higher construction costs. Inflated labor costs have already resulted in a 20% cost overrun for Chevron's (CVX) Gorgon liquefied natural gas project in Australia. And a Canadian oil sands boom—that has pushed wages for oil industry construction workers in Canada to 60% more than in the United States—is giving pause to companies such as Chevron, Royal Dutch, and National Petroleum, which have as many as nine liquefied natural gas terminals on Canada's West Coast on the drawing boards.
[By Matt DiLallo]
Argentina
The shale gas and oil resources in Argentina has the potential to really put the country at the forefront of the world's energy map. Not only does the country hold the fourth largest shale oil reserves, but it's also No. 2 in shale gas reserves. Investors looking to profit as the country develops these reserves could look at global giant Chevron (NYSE: CVX ) , which completed its first two exploratory wells into the Vaca Muerta formation last year, with another well currently being drilled. The company has three more appraisal wells planned, and given the vast reserve estimates for the country, this could be a big future driver for Chevron.
[By Ben Levisohn]
The Jones Industrials rose 0.6% to 16,064.77, a record high, while the S&P 500 gained 0.4% to 1.804.76, also an all-time high. Big Dow winners this week include JPMorgan Chase (JPM), which rose 4.7% this week after agreeing to a $13 billion settlement with the government, Chevron (CVX), which gained 3.3% to $124.03 after it suspended a North Sea oil project, and United Health Group (UNH), which advanced 2.6% to $73.74. In the S&P 500, Biogen Idec (BIIB) rose 17% to $285.62 after the European Union protected one of its drugs from competition and Tyson Foods (TSN), finished up 11% at $31.82 after reporting surprisingly good earnings.

5 Best Blue Chip Stocks To Invest In Right Now: Visa Inc.(V)

Visa Inc., a payments technology company, engages in the operation of retail electronic payments network worldwide. It facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities. The company owns and operates VisaNet, a global processing platform that provides transaction processing services. It also offers a range of payments platforms, which enable credit, charge, deferred debit, debit, and prepaid payments, as well as cash access for consumers, businesses, and government entities. The company provides its payment platforms under the Visa, Visa Electron, PLUS, and Interlink brand names. In addition, it offers value-added services, including risk management, issuer processing, loyalty, dispute management, value-added information, and CyberSource-branded services. The company is headquartered in San Francisco, California.

Advisors' Opinion:

[By Andrew Tonner]
Since both banks and credit card companies benefit from Apple Pay in much the same way, I'll further lump them together for purposes of this discussion. It doesn't take an overly keen observer to note that these combined financial institutions stand to gain as the result of Apple's new payment platform.�True, Apple Pay will eat into the value of each transaction (Apple reportedly receives $0.15 for every $100 of transactional value), but there's little question that the system's ease of use should help increase aggregate payment volumes for banks and expand the overall use of consumer credit for the credit card companies. �On top of seeing increased point-of-sale transaction volumes, these two kinds of financial institutions also believe Apple Pay will drive a significant uptick in mobile e-commerce sales by finally providing the kind of secure and seamless option many small websites need. �So while Apple will certainly eat into their margins, the credit card companies such as�Visa (NYSE: V ) , MasterCard (NYSE: MA ) , and American Express (NYSE: AXP ) �and major banks like�Wells Fargo (NYSE: WFC ) , JPMorgan Chase (NYSE: JPM ) , Citi (NYSE: C ) , are certainly right in their optimistic view of Apple Pay.

Monday, October 27, 2014

Top Medical Stocks To Own For 2014

Chinese companies often encounter hurdles getting their shares listed in the US, due to cultural and regulatory conflicts. Incidences of irregularities and outright fraud don’t help, either. China just can’t seem to shake the occasional business scandal that unnerves investors.

Events this week are the latest case in point.

A US Securities and Exchange Commission (SEC) administrative judge yesterday ruled that the Chinese joint ventures of the “Big Four” major global auditing firms should be banned from working for any US-listed Chinese companies for six months. The judge found that the four—Ernest & Young Hua Ming, KPMG Huazhen, Deloitte Touche Tohmatsu, and PwC Zhong Tian—had all engaged in deceptive accounting that violated the Sarbanes-Oxley Act.

However, you can rest easy over our China-based portfolio recommendations, such as AutoNavi Holdings (NSDQ: AMAP), China Petroleum & Chemical (NYSE: SNP) or Mindray Medical International (NYSE: MR). These major companies should remain untouched by the ruling.

Hot Cheap Companies To Watch For 2015: Euromedis Groupe SA (EMG)

Euromedis Groupe SA is a France-based company that specializes in the design, manufacture, distribution, rental and export of medical and surgical equipment and products, and services for medical home care for hospitals, clinics, retirement homes, physicians, pharmacies, and individuals. The Company's product portfolio include products, such as syringes and needles; surgical equipment, such as catheters, instrumentation and compresses; gloves; hygiene products, comprising disposable clothing, masks and paper towel products, and pharmaceutical equipment, offering cotton wool and thermometers. Euromedis Groupe SA exports its products to Europe and Africa. Advisors' Opinion:

[By Inyoung Hwang]
Man Group Plc (EMG) advanced 3.6 percent to 85.85 pence. The world�� largest publicly traded hedge-fund manager posted its first quarterly net inflows in two years as clients added money to funds at its GLG Partners unit. Sales of Man Group�� funds totaled $4.1 billion in the third quarter, exceeding $3.4 billion of redemptions.
[By Sofia Horta e Costa]
Man Group Plc (EMG) jumped 6.8 percent to 104.3 pence. The world�� largest publicly traded hedge-fund manager said it no longer needs to hold a $300 million capital buffer after it confirmed with the U.K.�� Financial Conduct Authority a change in the company�� regulatory status.
[By Sofia Horta e Costa]
Commodity producers increased as base metals rallied, with BHP Billiton Ltd. (BHP), the largest mining company, climbing 3.7 percent. Man Group (EMG) Plc soared 13 percent on a plan to redeem debt. Royal Bank of Scotland Group Plc dropped by the most in two months after Britain�� biggest state-owned lender reported operating profit that fell short of analysts��estimates.

Top Medical Stocks To Own For 2014: Cambridge Heart Inc (CAMH)

The Company competes with GE Medical Systems.

Advisors' Opinion:

[By Peter Graham]
Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:
Cambridge Heart, Inc (OTCMKTS: CAMH) Recently Changed Its Board
Small cap Cambridge Heart, Inc is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. On Friday, Cambridge Heart, Inc surged 176.92% to $0.018 for a market cap of $1.80 million plus CAMH is up 20% since the start of the year and down 86.1% over the past five years according to Google Finance.

Top Medical Stocks To Own For 2014: Portola Pharmaceuticals Inc (PTLA)

Portola Pharmaceuticals, Inc. (Portola), incorporated on September 2, 2003, is a biopharmaceutical company developing product candidates that have the potential to represent advances in the fields of thrombosis and hematology. The Company is advancing its three wholly owned programs using biomarker and genetic approaches.

Betrixaban

Portola's compound, betrixaban, is an oral, once-daily Factor Xa inhibitor being evaluated in the only biomarker-based Phase-III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Betrixaban's properties particularly suited to potentially demonstrate efficacy without increasing bleeding in this patient population.

Andexanet Alfa

Portola's second development candidate, andexanet alfa (PRT4445), has the potential to be a reversal agent to directly reverse the effects of Factor Xa inhibitors in patients who suffer a bleeding episode or who require emergency surgery. Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb and Pfizer (Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO [rivaroxaban]), and Daiichi Sankyo (Savaysa [edoxaban]), while retaining all decision-making and commercial rights to the program.

Cerdulatinib (PRT2070) and PRT2607

Portola's third wholly owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways - spleen tyrosine kinase (Syk) and janus kinase (JAK). It is being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations. Portola's fourth program is partnered with Biogen Idec and is focused on the development of PRT2607, a selective Syk inhibitor.

Advisors' Opinion:

[By Todd Campbell]
That leads me to Medivation (NASDAQ: MDVN ) , Ophthotech (NASDAQ: OPHT ) , and Portola (NASDAQ: PTLA ) , three companies with important therapies that may very well be destined to become top sellers.

Top Medical Stocks To Own For 2014: Biomerieux SA (BIM)

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, such as bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, bioMerieux Benelux SA/NV, among others. In January 2014, it acquired 100% stake in BioFire Diagnostics Inc. Advisors' Opinion:

[By Jonathan Morgan]
BioMerieux (BIM) jumped 3.8 percent to 76.53 euros, the largest gain in eight months. The French maker of tests for HIV and hepatitis reported sales for the first half of 754 million euros and confirmed its revenue-growth forecast.

Top Medical Stocks To Own For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

[By Ben Levisohn]
Stifel’s Dave Lutz calls retail “the main anchor on the tape today”– and we know what’s been happening with retail. Department stores are off about 1.5% as JC Penney (JCP), and Nordstrom (JWN) fall. Momentum stocks like Celgene (CELG), too, are also sagging. Add in a strengthening yen, and falling bond yields, and there you go.
[By Sean Williams]
Keep in mind that some companies�deserve�their current valuations. Celgene (NASDAQ: CELG ) , despite its already enormous rally, could have room to run higher according to RBC Capital, which expects big growth out of its drugs not named Revlimid. Based on Celgene's organic growth and expanding disease indications, it's very likely the company could hit its robust growth targets announced earlier this year of a doubling in revenue and a tripling in profits by 2017.
[By Bill Gunderson]
Last Tuesday, biotech stocks were selling off on Janet Yellen's congressional testimony when she voiced concerns about the valuation levels of smaller biotech and social media names calling them "substantially stretched.��Her comments sent the Biotech Index and bellwethers like Biogen (BIIB) , Celgene (CELG) and Gilead (GILD) all down 5% or more.
[By Mani]
Celgene Corporation (NASDAQ:CELG) plans to release its third quarter financial results on�Oct.24�and will host a conference call and live audio webcast on the same day at�9 a.m. ET�to discuss the financial and operational performance.

Top Medical Stocks To Own For 2014: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors' Opinion:

[By MONEYMORNING]
Inovio Zooms: We recommended biotech Inovio Inc. (NYSE: INO) at 71 cents a share back on Feb. 1, 2013, and have re-recommended it a number of times since. With their 15.2% gain yesterday, the shares are now at $3.71, up 414% from where we first told you about them - and we believe there's more to come. In fact, we'll be bringing you an interesting update on this company very soon. Inovio is one of 24 recommendations that have doubled or better since we launched Private Briefing back in August 2011.
[By Sean Williams]
No fairytale ending
Fairytale endings work great in the movies, but you rarely see them come to fruition in the real world. Small-cap biopharmaceutical Inovio Pharmaceuticals (NYSEMKT: INO ) has seen shares nearly triple since April on the heels of multiple intriguing studies, but will the glass slipper fit over the long term?

Sunday, October 26, 2014

Hot Quality Companies To Invest In 2014

LONDON -- To me, capital growth and dividend income are equally important. Together, they provide the total return from any share investment and, as you might expect, my aim is to invest in companies that can beat the total return delivered by the wider market.

To put that aim into perspective, the FTSE 100 has provided investors with a total return of around 3% per annum since January 2008.

Quality and value
If my investments are to outperform, I need to back companies that score well on several quality indicators and buy at prices that offer decent value.

So this series aims to identify appealing FTSE 100 investment opportunities and today I'm looking at�Rolls-Royce Holdings� (LSE: RR ) , the integrated power systems and services provider operating internationally in the aerospace, marine and energy markets.

With the shares at 1213 pence, Rolls-Royce's market cap. is 拢22,826 million.

This table summarises the firm's recent financial record:

Hot Industrial Disributor Companies To Own For 2015: Compressco Partners LP (GSJK)

Compressco Partners, L.P. is a provider of wellhead compression-based production enhancement services (production enhancement services). The Company provides its services to a base of natural gas and oil exploration and production companies operating throughout many of the onshore producing regions of the United States, as well as in Canada and Mexico. Its production enhancement services primarily consist of wellhead compression, related liquids separation, gas metering, and vapor recovery services. It also provides ongoing well monitoring services, and, in Mexico, automated sand separation services in connection with its primary production enhancement services. It design and manufacture most of the compressor units it use to provide its production enhancement services. Compressco Partners GP, Inc. is the general partner of the Company. In January 2014, the Company announced that it has completed the acquisition of Compression assets for gas lift markets as part of its defined strategic growth objectives.

GasJack unit fleet

The Company�� GasJack unit allows it to perform compression, liquids separation and optional gas metering services all from one skid. The Company focuses on the natural gas wells in its operating regions that produce between 30,000 and 300, 000 cubic feet of natural gas per day (Mcf/d) and less than 50 barrels of water per day. The Company primarily utilize its natural gas powered GasJack compressors, or GasJack units, to provide wellhead compression services. Its GasJack units increase gas production by reducing surface pressure, which allows wellbore fluids that would normally block gas flow to produce up the well. The 46-horsepower GasJack unit is an integrated power/compressor unit equipped with an industrial 460-cubic inch, V-8 engine that uses natural gas from the well to power one bank of cylinders that, in turn, powers the other bank of cylinders, which provide compression. As of December 31, 2011, the Company had a fleet of 3,145 GasJack units.!

VJack unit fleet

The Company utilizes its electric VJack compressors, or VJack units, to provide its production enhancement services on wells located in larger, mature oil fields, such as the Permian Basin in West Texas and New Mexico, and in environmentally sensitive markets, such as California, when electric power is available at the production site. Its VJack unit is designed for vapor recovery applications (to capture natural gas vapors emitting from closed storage tanks after production and to reduce storage tank pressures) and backside pumping applications on oil wells (to reduce pressures caused by casing head gas in oil wells with pumping units). Based on GasJack unit technology, the VJack unit is capable of full wellbore stream production, and can handle up to 50 barrels per day of liquids on a standard skid package. As of December 31, 2011, it had a fleet of 50 VJack units. Its GasJack and VJack compressor units are mounted on steel skids.

ePumper system

Utilizing its ePumper system, SCADA satellite telemetry-based reporting system, it remotely monitor in real time, whether its services are being continuously provided at each well site. The ePumper system improves the response time of its field personnel.

Well Monitoring and Automated Sand Separation Services

The Company also provides ongoing well monitoring services and, in Mexico, automated sand separation services. Its well monitoring services consist of ongoing testing and evaluation of wells to determine how its wellhead compression services are optimizing the production from a well.

Advisors' Opinion:

[By Jake L'Ecuyer]
Energy sector gained 0.85 percent in the US market today. Among the energy stocks, McDermott International (NYSE: MDR) was down more than 9.3 percent, while Compressco Partners LP (NASDAQ: GSJK) tumbled around 5.3 percent.
[By Jake L'Ecuyer]
Energy sector gained 0.85 percent in the US market today. Among the energy stocks, McDermott International (NYSE: MDR) was down more than 9.3 percent, while Compressco Partners LP (NASDAQ: GSJK) tumbled around 5.3 percent.
[By Marc Bastow]
Wellhead compression products manufacturer Compressco Partners (GSJK) raised its quarterly dividend 1.7% to 43.75 cents per share, payable on Feb. 14 to shareholders of record as of Jan. 31.
GSJK Dividend Yield: 7.60%

Hot Quality Companies To Invest In 2014: Foot Locker Inc (FL)

Foot Locker, Inc., incorporated on April 7, 1989, is a global retailer of shoes and apparel, operating 3,335 primarily mall-based stores in the United States, Canada, Europe, Australia, and New Zealand as of February 2, 2013. The Company operates in two segments: Athletic Stores and Direct-to-Customers. The Athletic Stores segment is an athletic footwear and apparel retailer whose formats include Foot Locker, Lady Foot Locker, Kids Foot Locker, Champs Sports, Footaction, and CCS. The Direct-to-Customers segment includes Footlocker.com, Inc. and other affiliates, including Eastbay, Inc. and CCS, which sell to customers through Internet websites, mobile devices, and catalogs. In September 2013, the Company acquired Runners Point Warenhandels GmbH (Runners) from Hannover Finanz GmbH.

Athletic Stores

Foot Locker is a global athletic footwear and apparel retailer. Its stores offer the products manufactured primarily by the athletic brands. Foot Locker offers products for a variety of activities, including basketball, running, and training. Additionally, the Company operates 65 House of Hoops, primarily a shop-in-shop concept, which sells basketball inspired products. Foot Locker�� 1,883 stores are located in 23 countries, including 1,072 in the United States, Puerto Rico, United States Virgin Islands, and Guam, 129 in Canada, 590 in Europe, and a combined 92 in Australia and New Zealand. The domestic stores have an average of 2,300 selling square feet and the international stores have an average of 1,500 selling square feet. Lady Foot Locker is a United States retailer of athletic footwear, apparel, and accessories for active women. Its stores carry athletic footwear and apparel brands, as well as casual wear and an assortment of apparel designed for a variety of activities, including running, walking, training, and fitness. In November 2012, the Company announced the introduction of a new banner named SIX:02. This new banner is an elevated retail concept featuring brand! s in fitness apparel and athletic footwear for women. Lady Foot Locker and SIX:02 operate 300 and 3 stores, and are located in the United States, Puerto Rico, and the United States Virgin Islands. These stores have an average of 1,300 selling square feet.

The Company�� Kids Foot Locker is a national children�� athletic retailer that offers a selection of brand-name athletic footwear, apparel and accessories for children. Its stores feature an environment geared to appeal to both parents and children. Its 305 stores are located in the United States, Puerto Rico, the United States Virgin Islands, Europe, and Canada. These stores have an average of 1,400 selling square feet. Footaction is a national athletic footwear and apparel retailer. Its 283 stores are located throughout the United States and Puerto Rico and focus on marquee footwear and branded apparel. The Footaction stores have an average of 2,900 selling square feet. Champs Sports is a mall-based specialty athletic footwear and apparel retailers in North America. Its product categories include athletic footwear and apparel, and sport-lifestyle inspired accessories. Its 539 stores are located throughout the United States, Canada, Puerto Rico, and the United States Virgin Islands. The Champs Sports stores have an average of 3,500 selling square feet. As of February 2, 2013, the Company operated 22 stores in the United States.

Direct-to-Customers

The Company�� Direct-to-Customers segment is multi-branded and multi-channeled. This segment sells, through its affiliates, directly to customers through its Internet websites, mobile devices, and catalogs. The Direct-to-Customers segment operates the Websites for eastbay.com, final-score.com, eastbayteamservices.com, ccs.com, as well as Websites aligned with the brand names of its store banners (footlocker.com, ladyfootlocker.com, kidsfootlocker.com, footaction.com, and champssports.com). Eastbay is a direct marketer in the United States, providing the high sch! ool athle! te with a sports solution, including athletic footwear, apparel, equipment, team licensed, and private-label merchandise. CCS serves the needs of the 12-20 year old seeking an authentic board lifestyle shop. CCS is anchored in skate but appealing to the surrounding board culture. The CCS format offers board lifestyle merchandise that will fit the needs of the customer all year long and stocks a selection of both core and lifestyle brands. The retail store operations of CCS are included in the Athletic Stores segment.

Advisors' Opinion:

[By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Foot Locker (NYSE: FL ) , whose recent revenue and earnings are plotted below.
[By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Foot Locker (NYSE: FL ) , whose recent revenue and earnings are plotted below.
[By Lee Jackson]
Consumer Discretionary: Foot Locker Inc. (NYSE: FL) offers an attractive risk/reward at its current level, with a solid road map to mid-single-digit comparisons and very solid mid-teens earnings per share (EPS) growth. The great thing for investors is that gym shoes wear out and are expensive. Credit Suisse has a $43 price target, and the consensus target is $39. Investors are paid a 2.3% dividend. A move to the Credit Suisse target would be a 26% gain for investors. The stock closed Tuesday at $34.01
[By Ben Levisohn]
In our opinion, this was a fine quarter with no surprises; however, as we expected expenses are accelerating resulting in guidance that implies a meaningful reduction to Q3 and Q4 estimates. Also, gross margin headwinds are mounting as the favorability from raw materials has turned and supply chain disruptions in Mexico will persist for two Q��. Given NKE�� premium 25x multiple, we prefer to play its strength through its retail partners ([Foot Locker (FL) and Finish Line (FINL)]).

Hot Quality Companies To Invest In 2014: Gladstone Commercial Corporation(GOOD)

Gladstone Commercial Corporation operates as a real estate investment trust (REIT) in the United States. It engages in investing in and owning net leased industrial and commercial real properties, and making long-term industrial and commercial mortgage loans. The company leases its real estate properties to small businesses, as well as to large public companies. As of December 31, 2009, it owned 64 properties, and held 1 mortgage loan. The company qualifies as a REIT under the Internal Revenue Code of 1986. As a REIT, it would not be subject to federal tax to the extent that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 2003 and is based in McLean, Virginia.

Advisors' Opinion:

[By GURUFOCUS]
Gladstone Commercial Corporation (GOOD) operates as a real estate investment trust (REIT) in the United States.Yield: 7.9%
Main Street Capital Corporation (MAIN) is a business development company specializing in long- term equity, equity related, and debt investments in small and lower middle market companies. Yield: 6.3%

Hot Quality Companies To Invest In 2014: Perceptron Inc.(PRCP)

Perceptron, Inc. develops, produces, and sells non-contact measurement and inspection solutions in the Americas, Europe, and Asia. It offers AutoGauge systems that are used in the assembly and fabrication plants of automotive manufacturers; AutoGauge Plus, which offers freeform surface scanning and discrete feature measurement in one solution; AutoFit systems that are used in automotive manufacturing plants to contain, correct, and control the fit of exterior body panels; AutoScan systems, which provide a non-contact method of gathering data for the analysis of the surface contour of a part or product; and AutoGuide systems to calculate the difference between theoretical and actual relationships of a robot and the part being assembled, and send compensation data in six degrees of freedom to the robot. The company also offers ScanWorks, a hardware/software component set that allows customers to add digitizing capabilities to their machines or systems; ScanWorks xyz, a 3D sc anning solution designed for retrofitting 3-axis machines; ToolKit, a software solution for CMM manufacturers, system integrators, and application software developers; WheelWorks software and sensors that offer a non-contact method of measuring wheel position for use in automated or manual wheel alignment machines in automotive assembly plants; and Multi-line Sensors for use in automotive assembly plant wheel alignment systems. In addition, it manufactures visual inspection devices and accessories for the mechanical market; plumbing diagnostic equipment, meter imager systems, line detector accessories, and handheld inspection devices for the plumbing market; optical inspection devices for the construction and DIY market; and imaging solutions for the electrical market, as well as offers value-added services, including training, field services, launch support, consulting, maintenance agreements, repairs, and software tools. The company was founded in 1981 and is headquartered in Plymouth, Michigan.

Advisors' Opinion:

[By Garrett Cook]
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.

Hot Quality Companies To Invest In 2014: Bonavista Energy Corp (BNPUF.PK)

Bonavista Energy Corporation (Bonavista) is engaged in the acquisition, exploration, development and production of oil and natural gas assets. The Company operates approximately 87% of its assets which are concentrated within three core regions in western Canada. Each core region contains a well-balanced portfolio of oil and natural gas assets with considerable opportunities. Its operations are geographically focused within three regions of Western Canada, which includes Western region, Northern region and Eastern region. The Company�� subsidiaries include Bonavista Petroleum (BP), Bonavista Energy LP (BELP) and Bonavista Energy Inc. (BEI). Advisors' Opinion:

[By Stephan Dube]
Cold Lake's most notable producers:
Husky Energy (HUSK.PK), see article here.Pengrowth Energy Corporation (PGH), see article here.Southern Pacific Resource (STPJF.PK), see article here.Canadian Natural Resources (CNQ), see article here.Devon Energy (DVN), see article here.Imperial Oil (IMO), see article here.Baytex, see article here.Bonavista Energy (BNPUF.PK), see article here.
Athabasca's most notable producers:

Hot Quality Companies To Invest In 2014: Enzon Pharmaceuticals Inc. (ENZN)

Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs. The company?s drug-development programs utilize two platforms-Customized PEGylation Linker Technology and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. It currently holds four compounds in clinical development and multiple novel LNA targets in preclinical research. The company?s development product pipeline consists of PEG-SN38 compound that utilizes Customized Linker Technology, which is in Phase II clinical trials for the treatment of metastatic colorectal and breast cancer, as well as a Phase I trial for pediatric patients with cancer; and the Hypoxia-Inducible Factor-1 alpha antagonist in Phase I studies for the treatment of solid tumors and lymphoma. Its product line also comprises Survivin antagonist in Phase I study in pediatric patients with recurrent acute lymphoblas tic leukemia; Androgen Receptor antagonist, a validated target for the treatment of prostate cancer that is in a Phase I study in patients with castration-resistant prostate cancer; and rights to five compounds, including AR, HER3, beta-catenin, PI3KCA, and Gli2. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Piscataway, New Jersey.

Advisors' Opinion:

[By Lisa Levin]
Enzon Pharmaceuticals (NASDAQ: ENZN) shares tumbled 28.28% to reach a new 52-week low of $1.15. Enzon Pharmaceuticals shares have dropped 63.30% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.
[By Bryan Murphy]
With just a quick glance at the company's recent news (or lack thereof), Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) doesn't look like anything all that special... or even trade-worthy. It only takes a brief look at the chart of ENZN, however, to conclude this stock - lack of new or not - has just become something trade-worthy, because the rest of the market has clearly started to fall back in love with it; there's no telling at what price the love affair could end.
[By Equities Lab]
The stocks that currently pass the stock screen in order of market cap are Frontier Communications Corp , Crown Media Holdings (CRWN), Vonage Holding (VG), MCG Capital Corp (MCGC), 1-800-FLOWERS.COM (FLWS), MTR Gaming Corporation (MNTG), Alaska Communications (ALSK), and Enzon Pharmaceuticals (ENZN).

Hot Quality Companies To Invest In 2014: ProLogis(PLD)

Prologis Inc. is an independent equity real estate investment trust. It invests in the real estate markets across the globe. The firm engages in the ownership, development, management, and leasing of industrial distribution and retail properties. It was previously known as Security Capital Investment Trust. Prologis Inc. was formed in 1991 and is based in San Francisco, California with an additional office in Denver, Colorado.

Advisors' Opinion:

[By Oliver Pursche]
As the real-estate crisis unfolded in 2008, Mr. Moghadam acted boldly and intelligently, taking advantage of opportunities around the world and eventually merging AMB with ProLogis (PLD) �in 2011 to create the current, a company who�� stock, since the bottom of the crisis in 2009, has outperformed the S&P 500.
[By Dimitra DeFotis]
Among real estate trusts:
American Tower��(AMT),�the diversified �REIT, is the best performer in the index.�It was�up 4.6% after saying�Friday it will buy the parent of tower operator Global Tower Partners for $4.8 billion. HCP (HCP), a healthcare REIT, was�up 3.3%. Prologis (PLD) an industrial REIT, was�up 2.8%. Vornado Realty Trust (VNO) was�up 2.7%. Boston Properties (BXP), the office REIT, was�up 2.3%. Equity Residential (EQR), a residential REIT, was�up 2.4%. Ventas (VTR), a healthcare REIT, was�up 2%.
[By Eric Volkman]
Prologis (NYSE: PLD ) has announced that it will sell 31 million new pieces of itself. That's the number of common shares it will float in an upcoming, underwritten public stock offering. The price of the shares will be $41.60 apiece, and the company's underwriters have been granted a 30-day purchase option for up to an additional 4.65 million shares to cover overallotments, if any.
[By Rich Duprey]
Industrial real estate developer Prologis� (NYSE: PLD ) �has declared regular and preferred dividends for the second quarter of 2013. The company plans to distribute $0.28 per share of its common stock on June 28 to shareholders of record as of June 11. For its�8.54% Series Q cumulative redeemable preferred stock, Prologis will distribute $1.0675 per share, which will be paid on July 1 to shareholders of record at the close of business on June 18.